Actually Kotak has a recent similar reco too.
Thanks for the discussion. And apologies for a poorly structured post to unwittingly take this thread in a different direction. That was not my intention. Rather, the post was for us to debunk the narrative / rationale put down by brokerage than blindly following (or being against) them. This allows us to cover any blind spot in our investment thesis.
Like for example what I wanted to ask was this:
- Do we believe that there is a downside risk for Synthesis sales for FY25?
- How do we compare Syngene with Laurus when we are investing our money?
- How did the previous brokerage comment of cessation of Paxlovid and lower ARV realisation pan out? Is this risk still valid now?
Disc: Invested and slowly accumulating
From an article published 16 hours back, in BQ prime.
Laurus’ exports rose 30% year-on-year to $30 million (ex-Paxlovid), but July to August sales were flattish, sequentially
P. S. Export data for August 2023, based on JM Financial’s report